sglt2 inhibitors (Wolters Kluwer Health)
86
Structured Review
Wolters Kluwer Health
sglt2 inhibitors
Sglt2 Inhibitors, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sglt2+inhibitors/sglt2i/10__1097_slash_qai__0000000000003854-155-21-2
Average 86 stars, based on 1 article reviews
Sglt2 Inhibitors, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sglt2+inhibitors/sglt2i/10__1097_slash_qai__0000000000003854-155-21-2
Average 86 stars, based on 1 article reviews
sglt2 inhibitors - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
other:Article Title: Are High- or Low-dose SGLT2 Inhibitors Associated With Cardiovascular and Respiratory Adverse Events? A Meta-analysis Article Snippet: The association between high-dose or low-dose sodiumglucose cotransporter 2 (SGLT2) inhibitors and various cardiovascular and respiratory serious adverse events (SAE) is unclear.. Our meta-analysis aimed to define the association between high-dose or low-dose SGLT2 inhibitors and 86 kinds of cardiovascular SAE and 58 kinds of respiratory SAE.. We included large cardiorenal outcome trials of SGLT2 inhibitors. Article Title: Sodium-glucose cotransporter 2 inhibitors and type 2 diabetes: clinical pearls for in-hospital initiation, in-hospital management, and postdischarge Article Snippet: Department of Anesthesia, Division of Cardiology, Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael’s Hospital, Department of Anesthesia, Department of Physiology, Department of Medicine, Department of Surgery, Department of Pharmacology and Toxicology, University of Toronto, Toronto, Division of Endocrinology and Metabolism, The Ottawa Hospital, University of Ottawa, Ottawa, Division of Endocrinology and Metabolism, Sunnybrook Health Sciences Centre, Department of Internal Medicine, Humber River Hospital, Toronto, Division of Endocrinology and Metabolism, Queen’s University, Kingston and LMC Diabetes & Endocrinology, Concord, Ontario, Canada Article Title: Development and Current Role of Sodium Glucose Cotransporter Inhibition in Cardiorenal Metabolic Syndrome Article Snippet: Sodium–glucose cotransporter-2 inhibitors were approved as adjunct therapy for the management of type 2 diabetes and have become a high-level recommendation for this population with cardiorenal metabolic syndrome.. In addition, evidence continues to grow supporting this class of medications for people with heart failure and chronic kidney disease, regardless of diabetes status.. This narrative review summarizes the sodium–glucose cotransporter inhibitors for cardiorenal metabolic syndrome. Article Title: Finerenone Proves Beneficial for Heart Failure with Preserved Ejection Fraction Article Snippet: Journal of Cardiovascular Pharmacology Publish Ahead of Print DOI: 10.1097/FJC.0000000000001636 1 Finerenone Proves Beneficial for Heart Failure with Preserved Ejection Fraction Giuseppe Biondi-Zoccai, MD, MStat 1,2 , Mattia Galli, MD, PhD 1,2 , George W. Booz, PhD 3 1 Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy 2 Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy 3 Department of Pharmacology and Toxicology, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA Running title: Finerenone and HFpEF Total word count: 1843 Funding: GWB was supported in part by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P20GM121334.. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.. Research leading to these results has received funding from the European Union - NextGenerationEU, through the Italian Ministry of University and Research, under PNRR - M4C2-I1.3 Project PE_00000019 "HEAL ITALIA" to GBZ: CUP B53C22004000006 Copyright © 2024 Wolters Kluwer Health, Inc. Article Title: Familial Renal Glucosuria and Potential Pharmacogenetic Impact on SGLT2 Inhibitors Article Snippet: Published by Activity Assay:Article Title: Effects of different doses of canagliflozin on blood pressure and lipids in patients with type 2 diabetes: a meta-analysis Article Snippet: Correspondence to Meiling Zhao, Department of Cardiology, Pre-Hospital Emergency Background: Canagliflozin is a sodium glucosecotransporter-2 receptor inhibitor approved for the treatment of type 2 diabetes mellitus (T2DM).. However, it is less prescribed due to increased LDL cholesterol (LDL-C), high incidence of urinary tract infection (UTI), high cost.. Data on the effect of canagliflozin on blood pressure (BP) are also limited. |